Learn more about our interactive marketing and application service offerings.

With the current Prescription Drug User Fee Act (PDUFA) expiring in September 2012, GAO was asked to examine and report on FDA’s drug and biologic review processes. The report examines trends in FDA’s NDA and BLA review performance for 2000 through 2010, FDA’s efficacy supplement review performance, and outlines steps FDA is taking to address issues raised about review processes.
The report resulted in a conclusion that FDA is "meeting most performance goals for reviewing drug applications."
The entire GAO report can be downloaded here.
